Mexico: Applying the experimental use exception in patent infringements

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Mexico: Applying the experimental use exception in patent infringements

Sponsored by

olivares-400px.jpg
greyson-joralemon-9ibqihqhuhc-unsplash.jpg

Armando Arenas of Olivares explores how Mexico has interpreted the experimental and academic use exception

For many years, the experimental and academic use exception was incorrectly applied in Mexico to declare third parties who imported raw materials while the patents that protected the correlative active principle were still in force, as infringers. This is because the companies alleged that, according to their import requests, these authorisations had been granted by the sanitary authorities for experimentation purposes without commercial aims.

Therefore, to avoid patent infringement, it was sufficient for the defendant to exhibit the import authorisation granted by the sanitary authority (Federal Commission for the Protection against Sanitary Risks COFEPRIS). The import authorisation also had to include a legend stating that the importation had been authorised for experimentation purposes.

Additionally, some infringing companies enforced the Roche-Bolar exception and the experimental use exception at the same time, generating confusion in the Mexican Institute of Industrial Property (IMPI). The institute chose to declare the raw material importing companies (trading companies) as infringers, considering that their activity was only for commercial purposes and denied the infringement if the defendants proved that they were pharmaceutical companies applying the benefit of the Roche-Bolar exception.

Recently, in cases handled by Olivares, two different circuit courts have clarified the correct interpretation of the experimental and academic use exception. The rulings  stated, in accordance with the most basic rules of the burden of proof, that it was not enough to exhibit an import permit that indicates that the destination of the raw material to consider that such exception is applicable. It stated that it was however necessary to demonstrate with another type of evidence, as they constitute their own facts and it was the defendants who asserted the said exception, which is the type of activity that was specifically carried out for purely experimental purposes. These new criteria have now caused the IMPI to correctly apply this exception for the benefit of the patent protection system and its holders.

 
Armando ArenasPartner, OlivaresE: armando.arenas@olivares.mx  

more from across site and SHARED ros bottom lb

More from across our site

New platform, which covers SEPs covering the Wi-Fi 6 and Wi-Fi 7 standards, includes 10 patent owners
The Texas-based IP litigation hires take King & Spalding’s partner appointments from pre-merger Winston & Strawn up to 12 this year
Sunny Su explains how her team overcame challenges with orchard evidence collection to secure a favourable plant variety decision from China’s top court
Flexible working firm continues trajectory from 2025 with appointment of Matthew Grant and Letao Qin
Anousha Davies, associate and trademark attorney at Birketts, unpicks how the university’s reputation enabled it to see off a proposed trademark for ‘Cambridge Rowing’
IP lawyers, who say they are encouraging clients to build up ‘tariff resilience’, should treat the risks posed by recent orders as a core consideration in cross-border licensing
Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Gift this article